The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS: We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage. The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group versus the ipilimumab group. RESULTS: At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]). The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group. The safety profile was unchanged from the initial report. Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. CONCLUSIONS: Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone. (Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“3-year overall survival rates were 58%, 52%, and 34% in combination therapy, anti-PD-1, and anti-CTLA-4 groups, respectively [4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [4]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These chemokines have been identified as the dominant mediators for the recruitment of CXCR3+ and CCR5+ tumor-specific T lymphocytes into the tumors and their intratumoral expression correlated with favorable clinical outcomes in patients with melanoma30–32.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [36]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 9×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 6×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 9×
“Increased amylase level 26 (8) 9 (3) 20 (6) 6 (2) 15 (5) 4 (1)”
InfluentialSelf-citationTime‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · cited 8×
“Asthenia 30 (10) 1 (<1) 25 (8) 1 (<1) 17 (5) 2 (1)”
InfluentialSelf-citation
Research works printed but not linked: 2
- Robert C, 2017, J Clin Oncol, 15, 35
- Long GV, Ann Oncol
Cited by
Sorted by citations
Items 501–600 of 1,021
Sussman, T. A., Li, H., Hobbs, B. P., Funchain, P., McCrae, K. R., & Khorana, A. A. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001719 · Cited by 126
Seitter, S. J., Sherry, R. M., Yang, J. C., Robbins, P. F., Shindorf, M. L., Copeland, A. R., McGowan, C. T., Epstein, M., Shelton, T. E., Langhan, M. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1171 · Cited by 120
Kvarnhammar, A. M., Veitonmäki, N., Hägerbrand, K., Dahlman, A., Smith, K. E., Fritzell, S., von Schantz, L., Thagesson, M., Werchau, D., Smedenfors, K., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0570-8 · Cited by 116
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 123
Lee, H., Quek, C., Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S. Y., Nur Gide, T., Shang, P., Attrill, G. H., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1537581 · Cited by 115
“8 months.(3,4) Despite this rapid advance in stage IV melanoma treatment, more than half of anti-PD-1 treated patients experience primary resistance to treatment, while approximately 30% of initial responders will eventually acquire resistance to anti-PD-1 therapy.”
BackgroundSelf-citationPreexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 117
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
Chang, C., Park, H., Malone, D. C., Wang, C.-Y., Wilson, D. L., Yeh, Y., van Boemmel-Wegmann, S., & Lo-Ciganic, W.-H. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1611 · Cited by 119
Geels, S. N., Moshensky, A., Sousa, R. S., Murat, C., Bustos, M. A., Walker, B. L., Singh, R., Harbour, S. N., Gutierrez, G., Hwang, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.013 · Cited by 124
Wang, K., Coutifaris, P., Brocks, D., Wang, G., Azar, T., Solis, S., Nandi, A., Anderson, S., Han, N. A., Manne, S., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.007 · Cited by 127
Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment
Garg, P. K., Pareek, S., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216537 · Cited by 131
“Importantly, the addition of pembrolizumab did not result in a marked increase in severe toxicity, making it a viable frontline treatment option for metastatic NSCLC patients with PD-L1 expression ≥ 1% [72,73].”
BackgroundNakamura, Y., Tanaka, R., Maruyama, H., Ishitsuka, Y., Okiyama, N., Watanabe, R., Fujimoto, M., & Fujisawa, Y. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy201 · Cited by 114
IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V. A., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0682 · Cited by 111
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 115
Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
Liu, J., O’Donnell, J. S., Yan, J., Madore, J., Allen, S. M., Smyth, M. J., & Teng, M. W. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1581530 · Cited by 112
“However, many patients received only 2 out of the 4 planned doses of immunotherapy due to an unexpectedly high proportion of these patients developing grade 3–4 irAEs (18/20)(6) which appeared higher than what would be predicted from Stage IV melanoma patients treated with the same combination immunotherapy.(15) Despi…”
BackgroundMuralidhar, S., Filia, A., Nsengimana, J., Poźniak, J., O'Shea, S. J., Diaz, J. M. S., Harland, M., Randerson‐Moor, J. A., Reichrath, J., Laye, J. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3927 · Cited by 115
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Mantuano, N. R., Natoli, M., Zippelius, A., & Laubli, H. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001222 · Cited by 114
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
Li, L., Zhang, F., Liu, Z., & Fan, Z. (2023) · Cancers · doi:10.3390/cancers15010321 · Cited by 123
Scientific Advances and New Frontiers in Mesothelioma Therapeutics
Mutti, L., Peikert, T., Robinson, B. W. S., Scherpereel, A., Tsao, A. S., de Perrot, M. E., Woodard, G. A., Jablons, D. M., Wiens, J., Hirsch, F. R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.011 · Cited by 112
“Lastly, even though MPM cells show a relatively low mutational load that can affect the sensitivity to immunotherapy, there is no doubt that the genetics, genedriven metabolism, and immune characteristics of this tumor are likely to unravel translational implications within the next few years.(23,29,132) It will be us…”
BackgroundNegrao, M. V., Lam, V. K. L., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 115
Ugurel, S., Röhmel, J., Ascierto, P. A., Becker, J. C., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Livingstone, E., Long, G. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.021 · Cited by 114
Self-citationIsik, B., Alexander, M. P., Manohar, S., Vaughan, L. E., Kottschade, L. A., Markovic, S. N., Lieske, J. C., Kukla, A., Leung, N., & Herrmann, S. M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.01.013 · Cited by 118
Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
Blanco, B., Domínguez-Alonso, C., & Álvarez‐Vallina, L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3770 · Cited by 117
“Several studies have demonstrated that combination of ICBs and TCEs maximized T-cell killing of tumor cells in vitro (69) and enhanced antitumor activity in a patient-derived xenograft model of leukemia (70).”
BackgroundInfluentialTumor metastasis: Mechanistic insights and therapeutic interventions
Liu, M., Yang, J., Xu, B.-S., & Zhang, X. (2021) · MedComm · doi:10.1002/mco2.100 · Cited by 124
van Not, O. J., Verheijden, R. J., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers‐Sonderen, M. J., de Groot, J. B., Hospers, G. A. P., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5041 · Cited by 112
Self-citationBispecific antibodies in cancer therapy: Target selection and regulatory requirements
Sun, Y., Yu, X., Wang, X., Yuan, K., Wang, G., Hu, L., Zhang, G., Pei, W., Wang, L., Sun, C., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.023 · Cited by 116
Lepletier, A., Madore, J., O’Donnell, J. S., Johnston, R. L., Li, X.-Y., McDonald, E., Ahern, E. S., Kuchel, A., Eastgate, M. A., Pearson, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3925 · Cited by 110
“One explanation for this might be the greater effectiveness of aPD1-combination therapy (26), resulting in more impressive RECIST response and survival outcomes for patients with favorable tumor CD155 expression.”
BackgroundSelf-citationNgiow, S. F., Manne, S., Huang, Y., Azar, T., Chen, Z., Mathew, D., Chen, Q., Khan, O., Wu, J. E., Alcalde, V., et al. (2024) · Cell · doi:10.1016/j.cell.2024.07.018 · Cited by 116
Melanoma pathology reporting and staging
Scolyer, R. A., Rawson, R. V., Gershenwald, J. E., Ferguson, P. M., & Prieto, V. G. (2019) · Modern Pathology · doi:10.1038/s41379-019-0402-x · Cited by 111
“melanoma patients treated with targeted or immune therapies [8, 9].”
BackgroundEvolving impact of long-term survival results on metastatic melanoma treatment
Michielin, O. A., Atkins, M. B., Koon, H. B., Dummer, R., & Ascierto, P. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000948 · Cited by 119
Self-citationAgonistic CD40 Antibodies in Cancer Treatment
Djureinovic, D., Wang, M., & Kluger, H. M. (2021) · Cancers · doi:10.3390/cancers13061302 · Cited by 113
BRAF Gene and Melanoma: Back to the Future
Ottaviano, M., Giunta, E. F., Tortora, M., Curvietto, M., Attademo, L., Bosso, D., Cardalesi, C., Rosanova, M., Placido, P. D., Pietroluongo, E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073474 · Cited by 125
Geuijen, C. A. W., Tacken, P. J., Wang, L.-C., Klooster, R., van Loo, P. F., Zhou, J., Mondal, A., Liu, Y.-B., Kramer, A., Condamine, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24767-5 · Cited by 114
Intracellular Self-Assembly of Peptides to Induce Apoptosis against Drug-Resistant Melanoma
Sun, M., Wang, C., Lv, M., Fan, Z., & Du, J. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00697 · Cited by 108
Shi, G., Yang, Q., Zhang, Y., Jiang, Q., Lin, Y., Yang, S., Wang, H., Cheng, L., Zhang, X., Li, Y., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.010 · Cited by 112
Single-cell genomic approaches for developing the next generation of immunotherapies
Yofe, I., Dahan, R., & Amit, I. (2020) · Nature Medicine · doi:10.1038/s41591-019-0736-4 · Cited by 107
Montfort, A., Filleron, T., Virazels, M., Dufau, C., Milhès, J., Pagès, C., Olivier, P., Ayyoub, M., Mounier, M., Lusque, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3449 · Cited by 110
Brown, L. C., Tucker, M. D., Sedhom, R., Schwartz, E. B., Zhu, J., Kao, C., Labriola, M., Gupta, R. T., Marin, D., Wu, Y. S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001792 · Cited by 105
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Brastianos, P. K., Kim, A. E., Giobbie‐Hurder, A., Lee, E. Q., Wang, N., Eichler, A. F., Chukwueke, U. N., Forst, D. A., Arrillaga‐Romany, I., Dietrich, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29052-7 · Cited by 113
The Treatment of Advanced Melanoma: Therapeutic Update
Villani, A., Potestio, L., Fabbrocini, G., Troncone, G., Malapelle, U., & Scalvenzi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126388 · Cited by 117
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma
Klobuch, S., Seijkens, T. T. P., Schumacher, T. N., & Haanen, J. B. A. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00848-w · Cited by 113
Self-citationCommon germline variants of the human APOE gene modulate melanoma progression and survival
Ostendorf, B. N., Bilanovic, J., Adaku, N., Tafreshian, K. N., Tavora, B., Vaughan, R. D., & Tavazoie, S. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0879-3 · Cited by 108
Peters, S., Reck, M., Smit, E. F., Mok, T. S. K., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz109 · Cited by 108
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Kang, J. H., Bluestone, J. A., & Young, A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.006 · Cited by 107
Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
Laenens, D., Yu, Y., Santens, B., Jacobs, J., Beuselinck, B., Bechter, O. E., Wauters, E., Staessen, J. A., Janssens, S. P., & Aelst, L. N. L. V. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01808 · Cited by 111
Self-citationKurt, F. G. Ö., Lasser, S., Arkhypov, I., Utikal, J. S., & Umansky, V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170762 · Cited by 111
Duerinck, J., Schwarze, J. K., Awada, G., Tijtgat, J., Vaeyens, F., Bertels, C., Geens, W., Klein, S., Seynaeve, L., Cras, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002296 · Cited by 113
Tostivint, E. P., Latouche, A., Vaflard, P., Ricci, F., Loirat, D., Hescot, S., Sablin, M., Rouzier, R., Kamal, M. T., Morel, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00114 · Cited by 112
“INTRODUCTION Immune checkpoint inhibitors (ICIs) that target cytotoxic T-lymphocyte protein-4 (CTLA-4) and programmed cell death protein 1 (PD-1) and its ligand PD-L1 have been demonstrated to improve overall survival (OS) in several tumor types.(1-12) In 2011, ipilimumab, a fully human immunoglobulin G1 monoclonal an…”
BackgroundA Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events
Naidoo, J., Zhang, J., Lipson, E. J., Forde, P. M., Suresh, K. S., Moseley, K. F., Mehta, S., Kwatra, S. G., Parian, A. M., Kim, A. K., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7268 · Cited by 107
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 114
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
Marletta, S., Fusco, N., Munari, E., Luchini, C., Cimadamore, A., Brunelli, M., Querzoli, G., Martini, M., Vigliar, E., Colombari, R., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071073 · Cited by 107
Mullinax, J. E., Hall, M. S., Prabhakaran, S., Weber, J. S., Khushalani, N. I., Eroglu, Z., Brohl, A. S., Markowitz, J., Royster, E. B., Richards, A. D., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00044 · Cited by 106
“Systemic immunotherapy using antibodies that block immune checkpoints to boost a tumor-specific immune response has been shown to improve overall survival for patients with unresectable metastatic melanoma and is now a standard treatment for most such patients (9, 10).”
BackgroundThe immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
Chen, H., Chong, W., Teng, C., Yao, Y., Wang, X., & Li, X. (2019) · Cancer Science · doi:10.1111/cas.14113 · Cited by 106
Cutaneous melanoma and the immunotherapy revolution (Review)
Leonardi, G. C., Candido, S., Falzone, L., Spandidos, D. A., & Libra, M. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5088 · Cited by 107
Human and mouse PD-L1: similar molecular structure, but different druggability profiles
Magiera‐Mularz, K., Kocik-Krol, J., Musielak, B., Plewka, J., Sala, D., Machula, M., Grudnik, P., Hajduk, M., Czepiel, M., Siedlar, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101960 · Cited by 107
Assessing the future of solid tumor immunotherapy
Guha, P., Heatherton, K. R., O’Connell, K. P., Alexander, I. S., & Katz, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030655 · Cited by 105
“Results of the outcomes after 3-year and 4-year follow-up of patients pointed towards the superior clinical benefits of combination therapy over monotherapy [62,63].”
BackgroundRecent developments with immunotherapy for hepatocellular carcinoma
Waidmann, O. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1499722 · Cited by 103
“Increased response rates but also increased toxicity in such combination therapies are expectable as found in other cancer diseases [22].”
BackgroundSafety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors
Chong, C. R., Park, V. J., Cohen, B., Postow, M. A., Wolchok, J. D., & Kamboj, M. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz202 · Cited by 105
Self-citationUveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types
van der Kooij, M. K., Speetjens, F. M., van der Burg, S. H., & Kapiteijn, E. (2019) · Cancers · doi:10.3390/cancers11060845 · Cited by 107
“treated with anti-PD1 and anti-CTLA4, 52% in patients with anti-PD1 monotherapy and 34% in patients treated with anti-CTLA4 monotherapy [108].”
MethodDonnelly, D. M., Bajaj, S., Yu, J.-H., Hsu, M. M., Balar, A. V., Pavlick, A. C., Weber, J. S., Osman, I., & Zhong, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0699-5 · Cited by 105
The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy
Woodall, M. J., Neumann, S., Campbell, K., Pattison, S. T., & Young, S. L. (2020) · Cancers · doi:10.3390/cancers12051230 · Cited by 110
Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
Young, A., Quach, H. T., Song, H., Davis, E. J., Moslehi, J. J., Ye, F., Williams, G. R., & Johnson, D. B. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000821 · Cited by 104
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 106
Wang, P., Ting-jian, W., Yang, Y., Yao, K., Li, Z., Li, Y. M., & Yan, C. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2844-2 · Cited by 105
Dorta-Estremera, S. M., Hegde, V. L., Slay, R., Sun, R., Yanamandra, A. V., Nicholas, C., Nookala, S. M. K., Sierra, G., Curran, M. A., & Sastry, K. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0728-4 · Cited by 108
Heinrich, S., Craig, A. J., Ma, L., Heinrich, B., Greten, T. F., & Wang, X. W. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.036 · Cited by 105
Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
Kohoutová, D., Worku, D. A., Aziz, H., TEARE, J. P., Weir, J., & Larkin, J. (2021) · Cells · doi:10.3390/cells10020327 · Cited by 111
Self-citationImmunotherapy in endometrial cancer: rationale, practice and perspectives
Cao, W., Ma, X., Fischer, J. V., Sun, C., Kong, B., & Zhang, Q. H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00301-z · Cited by 104
Gettinger, S. N., Redman, M. W., Bazhenova, L. A., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Bradley, J. D., Stinchcombe, T. E., Leighl, N. B., Ramalingam, S. S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2209 · Cited by 106
mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients
Bidram, M., Zhao, Y., Shebardina, N. G., Baldin, A. V., Bazhin, A. V., Ganjalikhany, M. R., Zamyatnin, A. A., & Ganjalıkhani-Hakemi, M. (2021) · Vaccines · doi:10.3390/vaccines9101060 · Cited by 111
Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.004 · Cited by 102
Self-citationJohnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 103
Towards Immunotherapy for Pediatric Brain Tumors
Wang, S. S., Bandopadhayay, P., & Jenkins, M. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.009 · Cited by 104
Sha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 102
“There were 35 studies with ICI alone arms totaling 13,956 patients (Supplemental Table 3).(36-71) Disease sites include cancers of head and neck, 42 stomach, 68 melanoma, 47, 50, 51, 56, 58, 59, 61, 62, 67, 70, 71 lung, 43-45, 55, 57, 60, 63, 64, 69 kidney, 53, 54, 65 prostate,(36) and urothelial origin.”
Weiss, S. A., Djureinovic, D., Jessel, S., Krykbaeva, I., Zhang, L., Jilaveanu, L. B., Ralabate, A. L., Johnson, B. J. B., Levit, N. S., Anderson, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0903 · Cited by 109
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Morello, S., Capone, M., Sorrentino, C., Giannarelli, D., Madonna, G., Mallardo, D., Grimaldi, A. M., Pinto, A., & Ascierto, P. A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1348-8 · Cited by 103
“Treatment of melanoma patients with nivolumab alone or in combination with ipilimumab has proved to induce an objective response rate (44–58%) higher than ipilimumab alone and a significantly longer progression-free survival [15, 19, 20].”
BackgroundSelf-citationKobold, S., Pantelyushin, S., Rataj, F., & Berg, J. V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00285 · Cited by 103
“In contrast, severe side effects of grade three or above are typically less frequent when targeting the CTLA4 or PD1 pathway with checkpoint blockade (∼28 and 21%, respectively) (59).”
BackgroundNKG2A, a New Kid on the Immune Checkpoint Block
Haanen, J. B. A. G., & Cerundolo, V. (2018) · Cell · doi:10.1016/j.cell.2018.11.048 · Cited by 104
Self-citationNF-κB and Its Role in Checkpoint Control
Betzler, A. C., Theodoraki, M., Schuler, P. J., Döscher, J., Laban, S. A., Hoffmann, T. K., & Brunner, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113949 · Cited by 106
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Robert, C., Marabelle, A., Herrscher, H., Caramella, C., Rouby, P., Fizazi, K. S., & Besse, B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0399-6 · Cited by 105
Effects of immune‐related adverse events ( irAEs ) and their treatment on antitumor immune responses
Blum, S. M., Rouhani, S. J., & Sullivan, R. J. (2023) · Immunological Reviews · doi:10.1111/imr.13262 · Cited by 105
“6,7 16 As murine tumor models typically utilized to study ICI efficacy do not develop severe irAEs, 17 insights into the relationship between irAEs and antitumor immunity have been guided by clinical observations and translational research.”
BackgroundCroce, G., Bobisse, S., Moreno, D. L., Schmidt, J., Guillame, P., Harari, A., & Gfeller, D. (2024) · Nature Communications · doi:10.1038/s41467-024-47461-8 · Cited by 109
Ebrahimi, H., Dizman, N., Meza, L., Malhotra, J., Li, X., Dorff, T., Frankel, P., Llamas-Quitiquit, M., Hsu, J., Zengin, Z. B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03086-4 · Cited by 109
Metabolic flexibility in melanoma: A potential therapeutic target
Ruocco, M. R., Avagliano, A., Granato, G., Vigliar, E., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.016 · Cited by 106
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment
Hanahan, D., Michielin, O. A., & Pittet, M. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00761-z · Cited by 106
Immunotherapy-related hepatitis: real-world experience from a tertiary centre
Cheung, V., Gupta, T., Payne, M., Middleton, M. R., Collier, J. D., Simmons, A., Klenerman, P., Brain, O., & Cobbold, J. (2019) · Frontline Gastroenterology · doi:10.1136/flgastro-2018-101146 · Cited by 102
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Zhang, C., & Liu, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01295 · Cited by 104
Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy
Sun, X., Zhang, N., Yin, C., Zhu, B., & Li, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00951 · Cited by 106
“The overall 3year survival rate was 58% in the nivolumab plus ipilimumab group, 52% in the nivolumab group, and 34% in the ipilimumab group, and the security data were not changed from the original report (90).”
BackgroundImmunotherapy in Prostate Cancer
Fay, E. K., & Graff, J. N. (2020) · Cancers · doi:10.3390/cancers12071752 · Cited by 103
ZEB1 transcription factor promotes immune escape in melanoma
Plaschka, M., Benboubker, V., Grimont, M., Berthet, J., Tonon, L., Lopez, J., Bouar, M. L., Balme, B., Tondeur, G., de la Fouchardière, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003484 · Cited by 104
Syeda, M. M., Wiggins, J. M., Corless, B. C., Long, G. V., Flaherty, K. T., Schadendorf, D., Nathan, P. D., Robert, C., Ribas, A., Davies, M. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30726-9 · Cited by 101
Self-citationGide, T. N., da Silva, I. P., Quek, C. Y. J., Ahmed, T., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Thompson, J. F., Batten, M., Long, G. V., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1659093 · Cited by 96
Self-citationPrinciples and Current Clinical Landscape of Multispecific Antibodies against Cancer
Elshiaty, M., Schindler, H., & Christopoulos, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115632 · Cited by 102
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 104
Schoenfeld, A. J., Antonia, S. J., Awad, M. M., Felip, E., Gainor, J. F., Gettinger, S. N., Hodi, F. S., Johnson, M. L., Leighl, N. B., Lovly, C. M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2151 · Cited by 98
Self-citationRecruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses
Bruchard, M., Geindreau, M., Perrichet, A., Truntzer, C., Ballot, E., Boidot, R., Racoeur, C., Barsac, E., Chalmin, F., Hibos, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01120-y · Cited by 106
An Update on Immunotherapy for Solid Tumors: A Review
Pham, T. D., Roth, S., Kong, J. C. H., Guerra, G., Narasimhan, V., Pereira, L. A., Desai, J., Heriot, A. G., & Ramsay, R. G. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6658-4 · Cited by 104
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122642 · Cited by 98
“Anti-CTLA-4 and anti-PD-1 combination therapy has already demonstrated improved clinical response rates in melanoma compared to either agent alone [85,86].”
BackgroundIntestinal microbiota: a new force in cancer immunotherapy
Dai, Z., Zhang, J., Wu, Q., Fang, H., Shi, C., Li, Z., Lin, C., Tang, D., & Wang, D. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00599-6 · Cited by 98
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 100
Metadata
- Authors
- Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M. S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P. A., Long, G. V., Cebon, J., Sosman, J., Postow, M. A., Callahan, M. K., Walker, D., Rollin, L., Bhore, R., Hodi, F. S., & Larkin, J.
- Affiliations
- University of Siena (IT)
- From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.),...
- ORCID
- Wolchok, Jedd D.
- Gonzalez, Rene
- Rutkowski, Piotr
- Grob, Jean-Jacques
- Cowey, C. Lance
- Wagstaff, John
- Schadendorf, Dirk
- Ferrucci, Pier F.
- Smylie, Michael
- Dummer, Reinhard
- Hogg, David
- Haanen, John
- Carlino, Matteo S.
- Bechter, Oliver
- Maio, Michele
- Guidoboni, Massimo
- McArthur, Grant
- Ascierto, Paolo A.
- Long, Georgina V.
- Cebon, Jonathan
- Sosman, Jeffrey
- Postow, Michael A.
- Callahan, Margaret K.
- Bhore, Rafia
- Hodi, F. Stephen
- Larkin, James
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-05
- Volume
- 377
- Issue
- 14
- Pages
- 1345-1356
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5706778
- OpenAlex
- W2753432434
- Semantic Scholar
- 23dbeed54cde655fb6a12697b02c9ff303515da7
- Cited by
- 5,357
- References
- 18
- Citations by year
- 2026: 159 · 2025: 282 · 2024: 569 · 2023: 705 · 2022: 746 · 2021: 947 · 2020: 900 · 2019: 578 · 2018: 428 · 2017: 37
- FWCI
- 234.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lirias (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- advanced melanoma, nivolumab, ipilimumab, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, overall survival, progression-free survival, treatment-related adverse events, immune-related adverse events, PD-L1 expression, BRAF mutation, long-term follow-up
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Humans, Melanoma, Middle Aged, Neoplasm Staging, Skin Neoplasms, Survival Rate, Disease-Free Survival, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
